Polaryx Taps CRO for Phase 2 Trial
Polaryx Therapeutics, a clinical-stage biotech company, announced it has selected a contract research organization (CRO) for its SOTERIA Phase 2 trial. The trial will evaluate the company's lead candidate, PLX-200, for treating four different rare, pediatric lysosomal storage disorders.
- The lead candidate, PLX-200, is a repurposed version of gemfibrozil, an FDA-approved drug traditionally used to regulate lipids. - The SOTERIA trial uses a "basket trial" design, an efficient strategy that allows researchers to test the effect of a single drug on multiple diseases—in this case, four—simultaneously within one study. - The four lysosomal storage disorders being investigated are CLN2 and CLN3 diseases (forms of Batten disease), Krabbe disease, and Sandhoff disease. - A Contract Research Organization (CRO) provides the infrastructure and expertise to run a clinical trial, managing everything from study design and patient recruitment to data analysis and ensuring compliance with regulations. This represents a technical career path in biotechnology, distinct from patient-facing medical roles. - The proposed mechanism for PLX-200 involves activating a protein called PPARα, which in turn helps the body produce more lysosomes (the cell's recycling centers) and has been shown to reduce neuroinflammation in animal models. - Preclinical data presented on February 6, 2026, showed that in mouse models of Krabbe disease, PLX-200 restored motor functions and increased lifespan, supporting the decision to advance to human trials. - Before this step, Polaryx had to get clearance from the U.S. Food and Drug Administration (FDA); the agency sent a "safe to proceed" letter for the SOTERIA trial in October 2025. - As a sign of its growth, Polaryx Therapeutics recently had its common stock approved
